PFE240802C32000
- 0.31
- +0.06+24.00%
Pfizer Newsroom
Daily short sale tracking: SoFi Technologies's short volume increased by 12 million, with a short sale ratio of 25%
Pfizer Marks First Revenue Growth Since COVID Revenue Peak In 2022, Lifts Annual Guidance
Pfizer in Charts: Primary Care Takes a Hit in Q2, Specialty Care and Oncology Thrive
Jim Cramer Says No To This Health Care Stock, Recommends Holding On To Constellation Energy: 'It's Up A Huge Amount'
Cost reduction and income increase! Pfizer Q2 performance exceeded expectations and raised full-year performance guidance.
Bet on weight loss drugs and anti-cancer drugs.
Today's Morning Movers and Top Ratings: CRWD, PFE, PYPL, DEO and More
In the post-pandemic era, the reconstruction sees the dawn and Pfizer (PFE.US) raises its full-year performance guidance.
Pfizer is trying hard to convince investors that its new drug product line can offset the significant decline in its COVID-19 vaccine and drug revenue, which has led to multiple downward revisions of expectations by management.
Pfizer Stock Rises After Guidance Hike, Earnings Beat.
US Stocks Outlook | Equity index futures rose together, microsoft (MSFT.US) announced earnings after the market close.
On July 30th (Tuesday) pre-market trading, US equity index futures rose together.
Stock Futures Edge Higher Ahead of Earnings, Labor Market Data; Asia Down, Europe Rises
JetBlue, Pfizer Earnings, Delta Reportedly Goes After CrowdStrike: Yahoo Finance
Pfizer Boost FY24 Outlook - Update
Pfizer's Stock Pops After Earnings Beat as Company Raises Guidance and Unveils Cost Cuts
Pfizer: Q2 Earnings Snapshot
Pfizer Inc. Q2 Profit Decreases, But Beats Estimates
Express News | Pfizer - Sees Potential That Higher Level of Cash Collections May Carry Over Into Q1 2025
Express News | Pfizer- Expect Heavy Weighting of Rev to Q4 as Business Has Become More Seasonal in Nature
Express News | Pfizer Sees Charge of About $400 Mln in Q3 After Decision in July to Sell One Facility After Discontinuation of Dmd Program
Express News | Pfizer: Expects to Resume Monetizing Our 23% Haleon Stake in the Future
Express News | Pfizer- Expect Operating Cash Flows to Be Significantly Below Typical Levels in 2024 & Particularly During H1 2024